On April 23-27, 2023, at the ARVO 2023 annual meeting held in New Orleans, USA, Dr. Archana from the University of Louisville presented on the safety and efficacy study results of RZ-004 in human mutant rhodopsin transgenic pig models on April 23, local time.

These results, derived from a collaborative study with Maureen A. McCall, a leading international authority on ocular diseases at the foreign institution of the University of Louisville, are significant in confirming the potential application of Rznomics’ RNA replacement enzyme-based gene therapy for ocular diseases.

Conference: 2023 ARVO Annual Meeting (The Association for Research in Vision and Ophthalmology)

Title: A ribozyme-mediated RNA replacement gene therapy shows efficacy in a pig model of Autosomal Dominant Retinitis Pigmentosa

Author: Archana Jalligampala¹, Kautuk Kamboj¹, Jennifer M. Noel¹, Elyse Frye¹, Joseph Prestigiacomo¹, Olivia Noelle Jacobs¹, Stephen Nash¹, Wei Wang¹, Ji-Hyun Kim², Seong-Wook Lee², Maureen A. McCall^1,3

¹ Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, Kentucky, United States

²R&D Center, Rznomics Inc., Seongnam 13486, Korea (the Republic of)

³Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, Kentucky, United States;